IL17A and skin basal cell carcinoma: However, there was no significant difference between SCC and BCC patients regarding serum levels of IL-17A.<h4>Conclusion</h4>According to our results, it can be concluded that IL-17A may play a role in inducing the growth and progression of NMSC and it can be used as a therapeutic target in these patients in future.